Parsons Awarded Option Year on Confidential Program

(NYSE:PSN), CHANTILLY, Va., Jan. 23, 2025 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today that the company was awarded a contract for a one-year option period on a confidential program in January 2025. This contract was noted as pending during the company's third quarter 2024 earnings conference call. About Parsons Parsons (NYSE: PSN) is […]

MU INVESTOR DEADLINE: Micron Technology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

RobbinsGeller Rudman & Dowd LLP announces that purchasers or acquirers of Micron Technology, Inc. (NASDAQ: MU) common stock between September 28, 2023 and December 18, 2024, both dates inclusive (the “Class Period”), have until March 10, 2025 to seek appointment as lead plaintiff of the Micron class action lawsuit. CaptionedKlein v. Micron Technology, Inc., No.

AMMD™ by Amy Myers, MD Unveils Newly Refreshed Line of Wellness Products

World-Renowned Functional Medicine Doctor Rebrands Accessible Solutions so Consumers Can Reclaim Their Health AMMD™, a wellness e-commerce platform and supplementline formulated and developed by world-renowned functional medicine doctor Amy Myers, MD, has relaunched its science-backed brandwith new product packaging, an updated website, and reduced pricing. https://mma.prnewswire.com/media/2604178/Candida_Support_Lifestyle.jpg With AMMD, Dr. Myers has made functional medicine more

ICON Energy Corp. Announces Pricing of Upsized $12.0 Million Public Offering

(NASDAQ:ICON), ATHENS, Greece, Jan. 23, 2025 (GLOBE NEWSWIRE) — Icon Energy Corp. (“Icon” or the “Company”) (Nasdaq: ICON), an international shipping company that provides worldwide seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels, today announced the pricing of its public offering of 9,160,305 units at a public offering price of

Aker Carbon Capture ASA announces that SLB Capturi has completed its first modular carbon capture plant

Aker Carbon Capture ASA (ACC ASA), an Aker Horizons portfolio company, announced that SLB Capturi has completed commissioning and is handing over its first modular carbon capture plant at Twence's waste-to-energy facility in Hengelo, Netherlands. The carbon capture plant is based on the standard, modular Just Catch™ design, which reduces onsite installation and outfitting work

Announcement of Tender Offer by Compañía de Minas Buenaventura S.A.A. for Any and All of its 2026 Notes

Compañía de Minas Buenaventura S.A.A. (“Buenaventura”) (NYSE: BVN)announced today that it has commenced a cash tender offer (the “Tender Offer”) for any and all of its outstanding 5.500% Senior Notes due 2026 (the “Notes”). The following table sets forth the material pricing terms of the Tender Offer: Title of Security CUSIP / ISIN Principal Amount

AbbVie Completes Acquisition of Nimble Therapeutics

— Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.

Aker Carbon Capture ASA announces that SLB Capturi has completed its first modular carbon capture plant

Aker Carbon Capture ASA (ACC ASA) is excited to announce that SLB Capturi has completed commissioning and is handing over its first modular carbon capture plant at Twence's waste-to-energy facility in Hengelo, Netherlands. The carbon captureplant is based on SLB Capturi's standard, modular Just Catch™ design, whichreduces onsite installation and outfitting work – providing a

LAPIX Therapeutics Doses First Patient-In Phase 1b Clinical Trial of LPX-TI641 for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)

LPX-TI641 is a novel, orally bioavailable, potent small-molecule immunomodulator that restores immune tolerance by targeting multiple pathways implicated in autoimmune diseases. Topline Phase 1 clinical data for LPX-TI641 in healthy volunteers demonstrated a generally well-tolerated safety profile and exposure-dependent, statistically significant increase in both regulatory T and B cells (T-regs and B-regs) compared to pooled

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of FTAI Aviation Ltd. (FTAI) Shareholders

NEW YORK CITY, NY / ACCESS Newswire / January 23, 2025 / If you suffered a loss on your FTAI Aviation Ltd. (NASDAQ:FTAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ftai-aviation-ltd-lawsuit-submission-form?prid=124621&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com

Scroll to Top